Literature DB >> 10469674

Optimising outcomes: socioeconomic perspective.

D B Mark1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10469674      PMCID： PMC1766501          DOI： 10.1136/hrt.82.2008.i18

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  2 in total

1.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

Authors:  M Cohen; C Demers; E P Gurfinkel; A G Turpie; G J Fromell; S Goodman; A Langer; R M Califf; K A Fox; J Premmereur; F Bigonzi
Journal:  N Engl J Med       Date:  1997-08-14       Impact factor: 91.245

2.  Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].

Authors:  D B Mark; P A Cowper; S D Berkowitz; L Davidson-Ray; E R DeLong; A G Turpie; R M Califf; B Weatherley; M Cohen
Journal:  Circulation       Date:  1998-05-05       Impact factor: 29.690
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.